Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.
Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.
复制标题
Y90 在肝细胞癌中的患者选择和临床结果。
DOI：
--
复制
发表时间：
2019
影响因子：
1.7
通讯作者：
S. Ganguli
中科院分区：
文献类型：
--
作者：
E. Wehrenberg;R. Gandhi;S. Ganguli
Y90 radioembolization is an alternative to transarterial chemoembolization for the intra-arterial treatment of hepatocellular carcinoma (HCC). However, the optimal treatment of HCC varies by tumor stage, underlying liver function and functional status, and local expertise. Therefore, the appropriate selection of patients for Y90 radioembolization is of paramount importance for optimal outcomes. Data on the role of Y90 radioembolization for HCC are most robust in the palliative treatment of inoperable, liver-confined disease. However, data are also present on the role of Y90 radioembolization as a bridge to or to downstage patients for transplant. Outcomes for radiation segmentectomy (ablative radiation doses) with curative intent or prior to resection are also discussed.
影响因子：
29.4
作者：
Salem R;Gordon AC;Mouli S;Hickey R;Kallini J;Gabr A;Mulcahy MF;Baker T;Abecassis M;Miller FH;Yaghmai V;Sato K;Desai K;Thornburg B;Benson AB;Rademaker A;Ganger D;Kulik L;Lewandowski RJ
通讯作者：
Lewandowski RJ